OPTIMIZING A POST-OPERATIVE PATHWAY IN RADICAL CYSTECTOMY PATIENTS REDUCES INFECTIOUS COMPLICATIONS

IF 2.4 3区 医学 Q3 ONCOLOGY
Randie E. White, Joshua Linscott, Connor Pelletier, Evelyn James, Erin Santos, Jeffrey M. Howard, Stephen T. Ryan, Matthew H. Hayn, Jesse D. Sammon
{"title":"OPTIMIZING A POST-OPERATIVE PATHWAY IN RADICAL CYSTECTOMY PATIENTS REDUCES INFECTIOUS COMPLICATIONS","authors":"Randie E. White,&nbsp;Joshua Linscott,&nbsp;Connor Pelletier,&nbsp;Evelyn James,&nbsp;Erin Santos,&nbsp;Jeffrey M. Howard,&nbsp;Stephen T. Ryan,&nbsp;Matthew H. Hayn,&nbsp;Jesse D. Sammon","doi":"10.1016/j.urolonc.2024.12.046","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Radical Cystectomy (RC) is a morbid procedure with a known high risk of complications and readmissions. Our institution is the only academic center in a rural state and provides the majority of cystectomy care, leading to a robust bladder cancer program. Longitudinally, a series of peri-operative changes to our RC care pathway have been made with the aim of improving outcomes. After the introduction of ERAS in 2020, we did not observe a change in outcomes which prompted a change in our perioperative pathway. Furthermore, genitourinary (GU) infections represented the largest body of post-operative complications amongst our complications. We describe the introduction of a post-operative discharge pathway (PODP), incorporated in 2022, aimed to reduce low-grade complications and associated readmissions.</div></div><div><h3>Methods</h3><div>Data was extracted from a prospectively maintained database identifying 323 RC pts from 2015-2024. Complications were graded and classified by the Memorial Sloan Kettering Cancer Center system. A statewide health information exchange allows for record sharing across institutions. This allowed for capture of complete 90d follow-up. All 90d readmissions, complications, and GU infections after surgery were recorded and analyzed.</div><div>An antibiogram specific to our RC pts was previously created, leading to prophylaxis (ppx) with low dose Levaquin or Bactrim starting POD#4 until stent removal at 2 weeks. This began April 1, 2022, as part of a larger PODP that included increased post-operative education, a post-discharge day 2 and 5 phone call with an oncology RN, and oral 30d DVT ppx post-discharge. Chi-square and multivariable logistic regression analyses were performed to assess the association between antibiotic ppx and 30 and 90d readmissions due to GU infection.</div></div><div><h3>Results</h3><div>90d follow-up was available for all 323 pts. 462 complications were recorded pre-PODP. 75.4% and 24.6% occurred at 30d and 90d, respectively. Infectious (27.3%), gastrointestinal (17.7%), and genitourinary (12.6%) causes were the most common, predominantly due to GU infections, ileus, and renal failure (Table 1). The majority were grade 2 (35.5%, Table 1<em>).</em> 30d and 90d mortality was 2.7% and 5.0%, respectively<em>.</em> Post-PODP implementation, 93 complications were recorded. 66.7% and 33.3% occurred at 30d and 90d, respectively. Gastrointestinal (33.3%), infectious (19.4%), and genitourinary (16.1%) causes were the most common (Table 1). The majority were grade 1 (23.4%, Table 1).</div><div>After PODP implementation, 53/56 pts received antibiotic ppx. The 30d risk of GU infections decreased following antibiotic ppx from 84/172 (48.0%) to 3/24 (12.5%), (p=0.001, Table 2). Of 66 pts readmitted at 30d pre-ppx, 41/66 (62.1%) were due to a GU infection vs 1/10 (10%) post-ppx (p=0.002, Table 2).</div></div><div><h3>Conclusions</h3><div>Here we show complete capture of follow-up for RC pts still living at 90d between 2015-2024. Our complications and readmissions are consistent with prior reports in both class and grade. Introduction of an updated PODP, which included targeted low dose daily antibiotics, increased education, and closer outpatient follow-up, led to reduction of our readmission rate due to GU infections and overall post-RC GU infection rate. Overall readmission rate is not statistically different, but limited by sample size and expected to be significant as the cohort increases.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 3","pages":"Page 18"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1078143924008263","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Radical Cystectomy (RC) is a morbid procedure with a known high risk of complications and readmissions. Our institution is the only academic center in a rural state and provides the majority of cystectomy care, leading to a robust bladder cancer program. Longitudinally, a series of peri-operative changes to our RC care pathway have been made with the aim of improving outcomes. After the introduction of ERAS in 2020, we did not observe a change in outcomes which prompted a change in our perioperative pathway. Furthermore, genitourinary (GU) infections represented the largest body of post-operative complications amongst our complications. We describe the introduction of a post-operative discharge pathway (PODP), incorporated in 2022, aimed to reduce low-grade complications and associated readmissions.

Methods

Data was extracted from a prospectively maintained database identifying 323 RC pts from 2015-2024. Complications were graded and classified by the Memorial Sloan Kettering Cancer Center system. A statewide health information exchange allows for record sharing across institutions. This allowed for capture of complete 90d follow-up. All 90d readmissions, complications, and GU infections after surgery were recorded and analyzed.
An antibiogram specific to our RC pts was previously created, leading to prophylaxis (ppx) with low dose Levaquin or Bactrim starting POD#4 until stent removal at 2 weeks. This began April 1, 2022, as part of a larger PODP that included increased post-operative education, a post-discharge day 2 and 5 phone call with an oncology RN, and oral 30d DVT ppx post-discharge. Chi-square and multivariable logistic regression analyses were performed to assess the association between antibiotic ppx and 30 and 90d readmissions due to GU infection.

Results

90d follow-up was available for all 323 pts. 462 complications were recorded pre-PODP. 75.4% and 24.6% occurred at 30d and 90d, respectively. Infectious (27.3%), gastrointestinal (17.7%), and genitourinary (12.6%) causes were the most common, predominantly due to GU infections, ileus, and renal failure (Table 1). The majority were grade 2 (35.5%, Table 1). 30d and 90d mortality was 2.7% and 5.0%, respectively. Post-PODP implementation, 93 complications were recorded. 66.7% and 33.3% occurred at 30d and 90d, respectively. Gastrointestinal (33.3%), infectious (19.4%), and genitourinary (16.1%) causes were the most common (Table 1). The majority were grade 1 (23.4%, Table 1).
After PODP implementation, 53/56 pts received antibiotic ppx. The 30d risk of GU infections decreased following antibiotic ppx from 84/172 (48.0%) to 3/24 (12.5%), (p=0.001, Table 2). Of 66 pts readmitted at 30d pre-ppx, 41/66 (62.1%) were due to a GU infection vs 1/10 (10%) post-ppx (p=0.002, Table 2).

Conclusions

Here we show complete capture of follow-up for RC pts still living at 90d between 2015-2024. Our complications and readmissions are consistent with prior reports in both class and grade. Introduction of an updated PODP, which included targeted low dose daily antibiotics, increased education, and closer outpatient follow-up, led to reduction of our readmission rate due to GU infections and overall post-RC GU infection rate. Overall readmission rate is not statistically different, but limited by sample size and expected to be significant as the cohort increases.
优化根治性膀胱切除术患者的术后路径可减少感染并发症
根治性膀胱切除术(RC)是一种病态的手术,已知并发症和再入院的风险很高。我们的机构是农村州唯一的学术中心,提供大部分的膀胱切除术治疗,导致一个强大的膀胱癌项目。纵向上,我们对RC护理路径进行了一系列围手术期改变,目的是改善预后。在2020年引入ERAS后,我们没有观察到结果的变化,这促使我们的围手术期途径发生了变化。此外,泌尿生殖系统(GU)感染是我们并发症中最大的术后并发症。我们描述了2022年引入的术后出院路径(PODP),旨在减少低级别并发症和相关的再入院。方法数据从前瞻性维护的数据库中提取,其中包括2015-2024年的323例RC pts。并发症由纪念斯隆凯特琳癌症中心系统分级和分类。全州范围的健康信息交换允许各机构之间的记录共享。这允许捕获完整的90d随访。所有90d的再入院、并发症和术后GU感染均被记录和分析。我们之前创建了针对RC患者的抗生素谱,导致从POD#4开始使用低剂量左旋喹或Bactrim进行预防(ppx),直到2周移除支架。从2022年4月1日开始,作为更大的PODP的一部分,包括增加术后教育,出院后第2天和第5天与肿瘤学注册护士通电话,以及出院后口服30d DVT ppx。采用卡方和多变量logistic回归分析来评估抗生素ppx与GU感染所致30和90d再入院之间的关系。结果323例患者均获得90d随访。podp前共记录462例并发症。30d和90d分别为75.4%和24.6%。感染性(27.3%)、胃肠道(17.7%)和泌尿生殖系统(12.6%)是最常见的原因,主要是由于GU感染、肠梗阻和肾功能衰竭(表1)。大多数是2级(35.5%,表1)。30d和90d死亡率分别为2.7%和5.0%。podp实施后,记录了93例并发症。30d和90d分别为66.7%和33.3%。胃肠道(33.3%)、感染性(19.4%)和泌尿生殖系统(16.1%)是最常见的原因(表1)。大多数是1级(23.4%,表1)。实施PODP后,53/56例患者接受了抗生素治疗。抗生素ppx后,30d的GU感染风险从84/172(48.0%)降至3/24 (12.5%)(p=0.001,表2)。在ppx前30d再次入院的66名患者中,41/66(62.1%)是由于GU感染,而ppx后为1/10 (10%)(p=0.002,表2)。结论:我们显示了2015-2024年期间仍然存活到90d的RC患者的完全随访。我们的并发症和再入院与班级和年级的先前报告一致。引入更新的PODP,其中包括有针对性的每日低剂量抗生素,增加教育和更密切的门诊随访,导致我们因GU感染再入院率和rc后总体GU感染率降低。总体再入院率在统计上没有差异,但受样本量的限制,随着队列的增加,预计会显著增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
3.70%
发文量
297
审稿时长
7.6 weeks
期刊介绍: Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信